Jove
Visualize
Contact Us

Related Experiment Videos

Quantification in clinical fluorodeoxyglucose positron emission tomography.

W A Hallett1

  • 1GlaxoSmithKline, Translational Medicine and Technology, Greenford, Middlesex, UK. william.hallett@kcl.ac.uk

Nuclear Medicine Communications
|June 23, 2004
PubMed
Summary

Clinical positron emission tomography (PET) uses simplified protocols for functional imaging, particularly with 2-[18F]fluoro-2-deoxy-D-glucose (F-FDG) in oncology. Despite resource limitations, relative metabolic rates are often sufficient, though optimal clinical quantification methods require further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing the Microsoft Kinect for Windows v2 for external head motion tracking for brain PET.

Physics in medicine and biology·2015
Same author

Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium.

European journal of nuclear medicine and molecular imaging·2003
Same author

Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer.

European journal of nuclear medicine·2001
Same author

alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.

Oncology research·1996
Same author

Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors.

Journal of medicinal chemistry·1993
Same author

Preparation of triazolo[1,5-c]pyrimidines as potential antiasthma agents.

Journal of medicinal chemistry·1990
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Nuclear medicine
  • Medical imaging
  • Oncology

Background:

  • Positron emission tomography (PET) provides crucial functional insights in clinical settings, especially for cancer detection.
  • The glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose (F-FDG) is a widely used radiotracer in clinical PET imaging.
  • Clinical PET protocols are often simplified compared to research methods due to resource, patient, and cost considerations.

Purpose of the Study:

  • To discuss the rationale behind simplified clinical PET imaging protocols.
  • To highlight the importance of relative metabolic rates in clinical PET quantification.
  • To identify unresolved questions in performing accurate quantification in clinical PET.

Main Methods:

  • Review of current clinical PET imaging practices.

Related Experiment Videos

  • Discussion of the trade-offs between simplified and research-grade PET protocols.
  • Analysis of the justification for using relative metabolic rates in clinical PET.

    • Main Results:

    • Simplified PET protocols are standard in clinical practice for efficiency and patient compliance.
    • Relative metabolic rates, rather than absolute values, are often the focus in clinical PET interpretation.
    • The need for optimized quantification strategies in clinical PET remains an open area of investigation.

    Conclusions:

    • Clinical PET, particularly with F-FDG, offers valuable functional information for disease assessment.
    • Standardized, simplified protocols are necessary for widespread clinical adoption and resource management.
    • Further research is essential to refine quantification techniques for improved clinical decision-making in PET imaging.